Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.

Autor: Bar-Or A; A Bar-Or Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street - 3 Gates Building, Philadelphia, PA 19104, USA.; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Wiendl H; Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany., Montalban X; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain., Alvarez E; Department of Neurology, Rocky Mountain MS Center, University of Colorado, Aurora, CO, USA., Davydovskaya M; Pirogov Russian National Research Medical University, Moscow, Russian Federation., Delgado SR; MS Center and Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA., Evdoshenko EP; St Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, St Petersburg, Russian Federation., Giedraitiene N; Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania., Gross-Paju K; West-Tallinn Central Hospital, Tallinn, Estonia/Institute of Health Care Technology, TalTech, Tallinn, Estonia., Haldre S; Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia/Neurology Clinic, Tartu University Hospital, Tartu, Estonia., Herrman CE; JWM Neurology, Indianapolis, IN, USA., Izquierdo G; Multiple Sclerosis Unit, Hospital Vithas NISA Sevilla, Sevilla, Spain., Karelis G; Neurology and Neurosurgery Department, Riga East University Hospital and Riga Stradins University, Riga, Latvia., Leutmezer F; Department of Neurology, Medical University of Vienna, Vienna, Austria., Mares M; Department of Neurology, Pardubice Regional Hospital, Pardubice, Czech Republic., Meca-Lallana JE; Multiple Sclerosis CSUR, Department of Neurology, Virgen de la Arrixaca Clinical University Hospital-IMIB-Arrixaca, Murcia, Spain/Clinical Neuroimmunology and Multiple Sclerosis Cathedra, Universidad Católica San Antonio (UCAM), Murcia, Spain., Mickeviciene D; Lithuanian University of Health Sciences, Kaunas, Lithuania., Nicholas J; OhioHealth Riverside Methodist Hospital, Columbus, OH, USA., Robertson DS; Multiple Sclerosis Division, Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA., Sazonov DV; Department of Clinical Trials FSBIH SDMC of FMBA of Russia, Novosibirsk, Russian Federation., Sharlin K; Sharlin Health and Neurology, Ozark, MO, USA., Sundaram B; Texas Institute for Neurological Disorders, Sherman, TX, USA., Totolyan N; Department of Neurology, First Pavlov State Medical University of St Petersburg, St Petersburg, Russian Federation., Vachova M; Department of Neurology, Teplice Hospital, Teplice, Czech Republic., Valis M; Department of Neurology, Faculty of Medicine in Hradec Králové, Charles University in Prague and University Hospital Hradec Králové, Hradec Králové, Czech Republic., Bagger M; Novartis Pharma AG, Basel, Switzerland., Häring DA; Novartis Pharma AG, Basel, Switzerland., Ludwig I; Novartis Pharma AG, Basel, Switzerland., Willi R; Novartis Pharma AG, Basel, Switzerland., Zalesak M; Novartis Pharma AG, Basel, Switzerland., Su W; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA., Merschhemke M; Novartis Pharma AG, Basel, Switzerland., Fox EJ; Central Texas Neurology Consultants PA, Round Rock, TX, USA.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 May; Vol. 28 (6), pp. 910-924. Date of Electronic Publication: 2021 Oct 04.

[New directions of immunocorrection in multiple sclerosis].

Autor: Boyko AN; Pirogov National Research Medical University, Moscow, Russia., Khachanova NV; Pirogov National Research Medical University, Moscow, Russia., Melnikov MV; Pirogov National Research Medical University, Moscow, Russia., Sivertseva SA; Tyumen Regional Center for Multiple Sclerosis, Tyumen, Russia., Evdoshenko EP; Pavlov First State Medical University of St. Petersburg, St. Peterburg, Russia., Spirin NN; Yaroslavl' State Medical University, Yaroslavl, Russia., Vasilyev AV; Neurology Scientific Center, Moscow, Russia., Rozenson OL; Merck KGaA, Moscow, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2020; Vol. 120 (2), pp. 103-109.

[Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].

Autor: Khachanova NV; Russian National Medical Research University named after N.I. Pirogov, Moscow, Russia., Bakhtiyarova KZ; Medical University of Bashkiriya, Ufa, Russia., Boyko AN; Russian National Medical Research University named after N.I. Pirogov, Moscow, Russia.; Federal Center for Cerebrovascular Pathology and Stroke, Moscow, Russia., Vlasov YV; Samara State Medical University, Samara, Russia., Davydovskaya MV; Russian National Medical Research University named after N.I. Pirogov, Moscow, Russia.; State Budgetary Institution of the Moscow region «Clinical and Economic Analysis Scientific-Practical Center of the Moscow Region Healthcare Ministry, Moscow, Russia., Evdoshenko EP; SPb Centre of Multiple Sclerosis and AID (City Clinical Hospital No31), St. Petersburg, Russia., Zakharova MN; Research Center of Neurology, Moscow, Russia., Kotov SV; State Budgetary Healthcare Institution of Moscow Region Moscow Regional Scientific Research Clinical Institute named after M.F. Vladimirsky, Moscow, Russia., Popova EV; Russian National Medical Research University named after N.I. Pirogov, Moscow, Russia.; Interdistrict Division of Multiple Sclerosis a the 24th City Hospital of Moscow, Moscow, Russia., Sivertseva SA; Tyumen Regional Centre of the Multiple Sclerosis, Tyumen, Russia., Totolyan NA; Federal State Budgetary Educational Institution of Higher Education First Saint Petersburg State Medical University named after Academician I.P. Pavlov of the Ministry of Healthcare of the Russian Federation, Saint Petersburg, Russia., Khabirov FA; Kazan State Medical Academy, Kazan, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2020; Vol. 120 (3), pp. 82-91.

[Provision of alemtuzumab safety is one of the main components of pharmacovigilance].

Autor: Khachanova NV; Pirogov Russian National Research Medical University, Moscow, Russia., Bakhtiyarova KZ; Bashkir State Medical University, Ufa, Russia., Boyko AN; Pirogov Russian National Research Medical University, Moscow, Russia., Vlasov YV; Samara State Medical University, Samara, Russia., Davydovskaia MV; Pirogov Russian National Research Medical University, Moscow, Russia; Scientific and Practical Center for Clinical Research and Medical Technologies Assessment of the Department of Health of the City of Moscow, Moscow, Russia., Evdoshenko EP; City Center of Multiple Sclerosis and Other Autoimmune Diseases City Clinical Hospital #31, St-Petersburg, Russia; Pavlov Saint-Petersburg State Medical University, St-Petersburg, Russia., Zakharova MN; Research Center of Neurology, Moscow, Russia., Malkova NA; Novosibirsk State Medical University, Novosibirsk, Russia., Sivertseva SA; Tyumen Regional Multiple Sclerosis Center, Tyumen, Russia., Spirin NN; Yaroslavl State Medical University, Yaroslavl, Russia., Stolyarov ID; Bechtereva Institute of Human Brain, St-Petersburg, Russia., Schmidt TE; Sechenov First Moscow State Medical University, Moscow, Russia., Khabirov FA; Kazan State Medical Academy, Kazan, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2018; Vol. 118 (8. Vyp. 2), pp. 82-87.

[Diagnostic value of immunoglobulin free light chains at the debut of multiple sclerosis].

Autor: Nazarov VD; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Makshakov GS; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia; City Clinical Hospital 31, St. Petersburg Center of multiple sclerosis and other autoimmune diseases, St. Petersburg, Russia., Mazing AV; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Surkova EA; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Krasnov VS; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Shumilina MV; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia; City Clinical Hospital 31, St. Petersburg Center of multiple sclerosis and other autoimmune diseases, St. Petersburg, Russia., Totolyan NA; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Evdoshenko EP; City Clinical Hospital 31, St. Petersburg Center of multiple sclerosis and other autoimmune diseases, St. Petersburg, Russia; Center of Clinical Trials Management and Performance of Moscow Department of Healthcare, Moscow, Russia., Lapin SV; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Emanuel VL; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia., Skoromets AA; Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2017; Vol. 117 (2. Vyp. 2), pp. 60-65.